Additionally, a phase II single-arm trial (NCT04329065) investigated the efficacy of WOKVAC combined with neoadjuvant taxane-based chemotherapy and HER2 antibody therapy (either TCHP or THP) in stage I-III HER2 + (HR ±) breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.